Overview

Tech Summary

Promoter Holding

Posts

SUNPHARMA

10123456789,001234567891012345678940123456789.1012345678950123456789
+0.35 (+0.03%)
The current prices are delayed.Login/Sign Up to see live prices.
Previous Close: 1013.8
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
1010
Today's high
1017.5
52 week low
922.45
52 week high
1023.85
Volume
1584079
About
Tech Summary
DMA(12)
₹1028.68
DMA(50)
₹988.87
DMA(100)
₹939.14
DMA(200)
₹907.73
Fund Summary
Market Cap
₹243325.01 Cr.
Enterprise Value
₹239581.96 Cr.
No. of Shares
239.93
P/E
28.72
RoE
7.21
Debt/Equity
0.03
Valuations
PE Chart
150200250300350400450
PB Chart
3.43.63.84.04.24.4
Promoter Holdings
Public : 9.41%
FII : 16.88%
DII : 19.24%
Promoter : 54.48%
Others : 0%
Charts
Debt/Equity
0.050.100.150.200.25
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
ROE vs ROCE
5.06.07.08.09.010.011.0
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
ROE
ROCE
Revenue vs Profitability (1000Cr.)
10203040
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
Revenue
Profit
Margins(%)
1015202530
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
Net Margin
Gross Margin
About
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Stock Sentiments
87% Bullish
13% Bearish
376 live trades of Rs. 21,516,926.36
K
kalirajchemist
 
Reputation: 0 • 
Just now
SUNPHARMA JUN23 1000 PE
7000 Qty (S) Exited-₹4,550
A
aman25
 
Reputation: 0 • 
Just now
SUNPHARMA JUN23 1000 CE
7000 Qty (B) Trade entered
Posts by FrontPage Users
NewsBot-display-image
Reputation: 44,958  •  Just now
Hot Stocks: Brokerage view on JSW Steel, Eicher Motors, SBI, Sun Pharma and Nykaa
Hot Stocks: Brokerage view on JSW Steel, Eicher Motors, SBI, Sun Pharma and Nykaa
Morgan Stanley has maintained an overweight rating on JSW Steel, SBI, Sun Pharma, and Nykaa, while initiating an equal-weight rating on Eicher Motors. The brokerage expects JSW Steel to reach a target price of Rs 580, with a reaffirmed volume guidance of 24.2mt, and sees a steady loan growth of 12-14% for SBI in FY24. Morgan Stanley also expects Sun Pharma to record a high single-digit growth for FY24, with a target price of Rs 1170, and sees Nykaa adding 50 new stores in FY24, with higher gross margins in the fashion segment.
The Economic Times
Comment
Share
Add a comment
T
Reputation: 1,582  •  Just now

# Sun pharmaceutical...read more
Chartbusters - chart - 72595915
1 Comment
Share
Add a comment
R
Reputation: 48  •  Jun 5 7:01 PM


Time Frame: 15 minutes
Confirmations:
1. daily price is near strong resistance (selling zone)
2. price consolidates between 1014-1010 (in 5 minutes time frame) showing buyers weakness
3. prices touches 18639.70 (near strong resistance zone)
4. evening star pattern i......read more
Chartbusters - chart - 71585887
1 Comment
Share
Add a comment
M
Reputation: 32  •  Jun 5 6:26 AM

SUN PHARMA
Trendline Breakout
TGT-1022/1050...read more
Chartbusters - chart - 71136874
Comment
Share
Add a comment
S
Reputation: 32  •  Jun 5 4:19 AM

S Pharma looks good on chart...read more
Chartbusters - chart - 71136761
Comment
Share
Add a comment
R
Reputation: 675  •  Jun 5 2:26 AM

Sunpharma is another stock which looks good for swing or short term trading because it has given breakout of pole and flag pattern on daily and weekly timeframe. volume is also good on these days
One can take position above if sustains above 1000
Stoploss in this condition wi......read more
1 Comment
Share
Add a comment
Gaganpreet-display-image
Reputation: 800  •  Jun 4 8:13 PM
5 Comments
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  Jun 3 9:31 PM
Global inflows help Indian stocks become EM Asia’s top gainers
Global inflows help Indian stocks become EM Asia’s top gainers
Foreign investors have increased inflows into Indian stocks to a nine-month high in May. They purchased a net $5bn of the countrys shares last month, the most since August, according to Bloomberg. The purchases continued for 24 consecutive days, the longest string since August last year. The surge in investment has propelled Indian equities to the top of emerging Asia's leaderboard, with the Nifty 50 Index up over 6%. The robust growth of the Indian economy is a significant selling point for foreign investors, particularly with China exhibiting less momentum and fears growing in the US of an economic downturn.
The Economic Times
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  Jun 2 1:31 AM
Adani group will thrive with or without Modi, bets GQG’s Jain
Adani group will thrive with or without Modi, bets GQG’s Jain
Rajiv Jain, chief investment officer at GQG Partners, has reaffirmed his fund's commitment to India, holding around $13bn in the country's stocks, despite broader investor worries about corporate governance and political risk. Jain added that he and his colleagues were looking to buy more, with Indian infrastructural projects presenting new opportunities. He also defended his decisions to invest some $2.5bn into beleaguered conglomerate Adani Group.
The Economic Times
Comment
Share
Add a comment
T
Reputation: 1,582  •  Jun 1 6:08 PM

Tf of 1D
Take tread when price touch the above line.
Chartbusters - chart - 70073568
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  Jun 1 5:53 PM
Buy Sun Pharmaceutical Industries; target of Rs 1172: KR Choksey
Buy Sun Pharmaceutical Industries; target of Rs 1172: KR Choksey
KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023.
Moneycontrol
Comment
Share
Add a comment
Big Shot Trader-display-image
Reputation: 3,056  •  Jun 1 4:38 PM

Sunpharma fut range to sell 983_986
SL 997
Target 965
Chartbusters - chart - 69941182
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  Jun 1 4:36 PM
Buy Sun Pharmaceutical Industries, target price Rs 988.7 :  ICICI Direct
Buy Sun Pharmaceutical Industries, target price Rs 988.7 : ICICI Direct
Sun Pharmaceutical Industries, incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 235134.83 Crore) operating in Promoters held 54.48 per cent stake in the company as of 31-Mar-2023, while FIIs owned 16.88 per cent, DIIs 19.07 per cent.Pharmaceuticals sector.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 31 5:28 PM
Buy Sun Pharmaceutical Industries; target of Rs 1123: Sharekhan
Buy Sun Pharmaceutical Industries; target of Rs 1123: Sharekhan
Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1123 in its research report dated May 29, 2023.
Moneycontrol
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 31 5:16 AM
'Sun Pharma eyes deals to push specialty play, EM business'
'Sun Pharma eyes deals to push specialty play, EM business'
Sun Pharma, India's largest drugmaker, is looking at acquisitions to boost its specialty pipeline and strengthen emerging markets business. "Our focus on M&A will be on augmenting the pipeline for specialty and further strengthening our footprint in emerging markets," said CS Muralidharan, chief financial officer of Sun Pharma.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 30 11:01 PM
Share market update: Most active stocks in today's market in terms of volume
Share market update: Most active stocks in today's market in terms of volume
The NSE Nifty index closed 35.2 points up at 18633.85
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 30 8:23 PM
Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand
Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand
The companies have come together to commercialise Philogen's speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement.
Moneycontrol
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 30 8:11 PM
Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand
Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand
Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand. The companies have come together to commercialise Philogen's speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 30 12:11 PM
Sun facing some clouds is still a buy for analysts
Sun facing some clouds is still a buy for analysts
Shares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% from the previous close. More than 5.6 million shares exchanged hands on the BSE and NSE on Monday, over twice its combined average daily volume for the last month.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 29 8:38 PM
Buy Sun Pharmaceutical Industries; target of Rs 1140: Prabhudas Lilladher
Buy Sun Pharmaceutical Industries; target of Rs 1140: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1140 in its research report dated May 28, 2023.
Moneycontrol
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 29 8:01 PM
All our businesses are well positioned for growth : CS Muralidharan, Sun Pharma
All our businesses are well positioned for growth : CS Muralidharan, Sun Pharma
At this point of time, Taro has not given any specific guidance as such and continues to be a public company. So we will be unable to offer any comment on the future performance of Taro either on the current asset basis or even if the transaction goes through. It is too early to comment.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 29 7:08 PM
Buy Sun Pharma; target of Rs 1160: Motilal Oswal
Buy Sun Pharma; target of Rs 1160: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1160 in its research report dated May 27, 2023.
Moneycontrol
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 29 4:11 PM
Markets to go much higher than current levels over next few months: Sandip Sabharwal
Markets to go much higher than current levels over next few months: Sandip Sabharwal
​Now, one can argue that a part of that is built into the stock prices, but I think this entire theory of worst is over, best is over and trying to juggle portfolios based on that is not a strategy which works very well. So we have to ride the winners till a point of time valuations become very high and the gap becomes excessive, which I do not think has happened still.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 29 3:18 PM
Sun Pharma trades lower. Here's what brokerages have to say on Q4 earnings
Sun Pharma trades lower. Here's what brokerages have to say on Q4 earnings
Sun Pharmaceutical Industries reported a net profit of Rs 1,984.5 crore for the quarter ended March against a loss of Rs 2,227.38 crore a year ago.
Moneycontrol
Comment
Share
Add a comment
H
Reputation: 240  •  May 29 7:01 AM

Sunpharma Daily
Near support bullish candle wih high volumes
False breakout confirmation
Buy - 970 , SL - 940...read more
Chartbusters - chart - 67718738
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 28 3:21 PM
Despite the run-up, Reliance continues to be nicely balanced: Gurmeet Chadha, Complete Circle Consultants, pharma stocks outlook
Despite the run-up, Reliance continues to be nicely balanced: Gurmeet Chadha, Complete Circle Consultants, pharma stocks outlook
“It has been a while since Reliance Industries consolidated. The earnings were pretty strong. The O2C segment did pretty well while Jio continues and retail continues to get more traction. Also, the demerger of Jio Financial Services was another small trigger and the market was valuing it at about Rs 200-220.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 28 1:21 AM
Sun Pharma names Aalok Shanghvi as whole-time director
Sun Pharma names Aalok Shanghvi as whole-time director
Sun Pharma Board has appointed Aalok Shanghvi as a whole-time director for a five-year term beginning June 1, 2023. Shanghvi, the son of Sun Pharma's founder-promoter and managing director Dilip Shanghvi, has been heading key functions, including emerging markets, global generic R&D, global generic business development, and active pharmaceutical ingredient since joining the firm in 2006. The board also approved Rolf Hoffmann's appointment as an independent director for the next five years. Hoffmann has extensive experience in managing worldwide markets and creating commercial opportunities, having previously worked as an executive at Eli Lilly and Amgen.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 27 5:01 PM
Sun Pharma offers to acquire 100% stake in Taro in an all-cash deal
Sun Pharma offers to acquire 100% stake in Taro in an all-cash deal
Sun Pharmaceutical Industries has proposed an all-cash acquisition of all the shares of Taro Pharmaceutical Industries through a reverse triangular merger at a price of $38 per ordinary share. Sun Pharma said that the proposal represents a premium of 31.2% over Taro's closing price on May 25, 2023. After the deal, Sun Pharma will have a 100% holding in the company. The all-cash transaction will be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999. The deal is subject to fulfillment of binding contractual documentation and regulatory approvals.
The Economic Times
Comment
Share
Add a comment
Js7771017-display-image
Reputation: 40  •  May 27 4:15 AM

Sunpharma 31-46...read more
Chartbusters - 67714190
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 27 3:01 AM
Sun Pharma reports Rs 1,985 crore net profit in Q4FY23
Sun Pharma reports Rs 1,985 crore net profit in Q4FY23
Sun Pharma posted a net profit of INR 1,985 crore ($266m) in Q4 FY23 due to increased specialty drug sales and strong growth in domestic formulations and emerging markets. The firm made a net loss of INR 2,277 crore in the same quarter of the previous year. The adjusted net profit for Q4 FY23, excluding exceptional items, was INR 2,156 crore. The company's gross revenue climbed 14.3% year-on-year to INR 10,726 crore, while its EBITDA increased 19.7% YoY to INR 2,802 crore.
The Economic Times
Comment
Share
Add a comment
Add a comment
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 26 8:33 PM
Sun Pharma Q4 result: Net profit at Rs 1,984.5 crore, tops estimate
Sun Pharma Q4 result: Net profit at Rs 1,984.5 crore, tops estimate
Sun Pharma Q4 result: Analysts had pegged Sun Pharma's net profit for the fourth quarter at Rs 1,808.1 crore.
Moneycontrol
Comment
Share
Add a comment
Harsh Doshi-display-image
Reputation: 3,528  •  May 26 8:23 PM


Sun Pharma has recently broken a crucial resistance level 200 EMA on its daily chart, supported by a strong bullish candle and substantial trading volume. With a solid base formation preceding the breakout, this presents an enticing entry opportunity for swing trader......read more
Chartbusters - chart - 67630339
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 25 10:41 PM
Share market update: Most active stocks in today's market in terms of volume
Share market update: Most active stocks in today's market in terms of volume
The NSE Nifty index closed 35.75 points up at 18321.15
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 25 8:21 PM
Granules India reports 'information security incident'; isolates impacted IT assets
Granules India reports 'information security incident'; isolates impacted IT assets
The appropriate containment and remediation actions are being taken in a controlled manner to address the incident, it added. In March, Sun Pharma also reported an information security incident at the company.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 23 4:21 PM
2 sectors Digant Haria is bullish on for near term
2 sectors Digant Haria is bullish on for near term
I think pharma has multiple legs so one part of pharma which has sort of consumer kind of characteristics and the second kind of pharma is which have commodity kind of characteristics.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 23 4:16 PM
Hot Stocks: Brokerage view on BPCL, Sun Pharma, Thermax, Shree Cement and Power Grid
Hot Stocks: Brokerage view on BPCL, Sun Pharma, Thermax, Shree Cement and Power Grid
Top brokerage firms have released their recommendations for various companies. BofA Securities maintained an underperform rating on BPCL and Citi maintained a buy rating on Sun Pharma and Power Grid. Goldman Sachs retained its sell rating on Thermax, while Jefferies issued a hold rating on Shree Cement. Despite BPCL's Rs 7,840 crore Q4 PAT, BofA Securities maintained a target price of Rs 315. Citi believes that Sun Pharma is among the top picks in the Indian Pharma space.
The Economic Times
Comment
Share
Add a comment
Trade The Momentum -display-image
Reputation: 16,771  •  May 22 4:16 AM

- SUNPHARMA -
• 22 / May
• Already shared my view it was on Rs 951
• Buying zone will be 920-900
• Stoploss will be below 900
Chartbusters - chart - 64168243
3 Comments
Share
Add a comment
Elliott Wave-display-image
Reputation: 30,781  •  May 17 4:59 PM


Market giving good opportunity

With our best trading setups

Need to wait for proper time

Like Apna time ayega

or Jab ayega tab Focus on Execution
Chartbusters - chart - 62283032
Comment
Share
Add a comment
M
Reputation: 32  •  May 12 2:59 PM

Chart analysis
Formation of W pattern in sun pharma...read more
Chartbusters - chart - 60235951
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 10 11:16 AM
Mankind Pharma rallies 32% on day 1
Mankind Pharma rallies 32% on day 1
At Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fifth largest pharma company by market value of ₹57,046 crore. Sun Pharma, Divi's Lab, Dr. Reddy's Lab, and Cipla are currently valued between ₹75,284 crore and ₹2.31 lakh crore.
The Economic Times
Comment
Share
Add a comment
Harsh Doshi-display-image
Reputation: 3,528  •  May 9 6:41 PM


Based on the daily time frame, Sun Pharma is currently at a critical support zone, which makes it an important area to watch for traders. During today's trading session, Sun Pharma took resistance from its 200-day exponential moving average (EMA) and has since broken......read more
Chartbusters - chart - 58641330
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 9 3:41 PM
Hot Stocks: Brokerages view on Kfin Tech, Sun Pharma, Pidilite and Exide
Hot Stocks: Brokerages view on Kfin Tech, Sun Pharma, Pidilite and Exide
Morgan Stanley has given an 'overweight' rating to Sun Pharmaceuticals, citing several upcoming growth factors. JP Morgan has also rated Exide Industries and Kfin Technologies as 'overweight' and 'neutral', respectively, while Citi has a 'buy' rating on Exide. JP Morgan has given an 'underweight' rating to Pidilite Industries. The company's earnings missed expectations, but its gross margin recovered and the demand narrative was cautiously optimistic, it said.
The Economic Times
Comment
Share
Add a comment
R
Reputation: 4,622  •  May 9 3:06 AM

👉See the chart pattern and what is your observation in this chart.
👉 What is the next move in SUNPHARMA.
➡️ H&S Pattern in SUNPHARMA.
➡️ Only educational purposes.
Chartbusters - chart - 58275972
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 8 10:16 PM
Share market update: Most active stocks in today's market in terms of volume
Share market update: Most active stocks in today's market in terms of volume
The NSE Nifty index closed 195.4 points up at 18264.4
The Economic Times
Comment
Share
Add a comment
Trade The Momentum -display-image
Reputation: 16,771  •  May 8 9:46 PM

Sun Pharma
Timeframe : 1 day
- Harmonic : AB = CD
Buying range : 925-900
Sl : below 895
Target : 975/1025/1100
Analysis yourself before taking any trade
Manage your risk
Save your capital
Chartbusters - chart - 58263131
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 7 5:01 PM
Sun Pharma recalls over 24K prefilled syringes of generic medication in the US
Sun Pharma recalls over 24K prefilled syringes of generic medication in the US
In its latest Enforcement Report, the US Food and Drug Administration (USFDA) noted that the Mumbai-based drug major is recalling 24,194 prefilled syringes of Fyremadel (ganirelix acetate) injection. The company is recalling the affected lot due to the presence of particulate matter, the USFDA said.
The Economic Times
Comment
Share
Add a comment
K
Reputation: 16  •  May 5 5:13 AM

sunpharma reached demand zone in 1day tf
if breaks todays day high them more upmove possible
Chartbusters - chart - 57014733
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 44,958  •  May 2 10:46 PM
Share market update: Most active stocks in today's market in terms of volume
Share market update: Most active stocks in today's market in terms of volume
The NSE Nifty index closed 82.65 points up at 18147.65
The Economic Times
Comment
Share
Add a comment
Load More Posts